1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Magle Chemoswed Holding AB (publ)

Magle Chemoswed Holding AB (publ)

MAGLE.ST
Magle Chemoswed Holding AB (publ)SE flagStockholm Stock Exchange
1.00
SEK
- -
- -
20.65MMarket Cap
Magle Chemoswed Holding AB (publ)
MAGLE.ST
(Stockholm Stock Exchange)

Recent

price

1.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.38
12.5
18.71
12.31
13.49
15.83
11.5
13.02
13.08
Revenue per Share
-0.32
0.07
0.24
0.4
0.85
1.13
0.31
-12.23
-8.75
Basic EPS, GAAP
-0.97
-6.07
-2.36
1.32
-0.41
0.02
-1.36
-3.3
-3.69
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.36
1.44
2.26
2
2.76
3.84
2.34
-9.9
- -
Book Value per Share
3.77
8.39
11.42
5.7
5.95
6.94
11.76
2.53
2.3
Tangible Book Value per Share
10
10
8
11
11
11
21
21
21
Basic Weighted Avg Shares
106
128
142
132
146
170
236
268
270
Sales/Revenue/Turnover
-3.67
0.82
3.43
3.8
10.16
10.8
3.77
-87.69
-58.12
Operating Margin (%)
7
13
12
12
13
13
28
191
95
Depreciation Expense
-3
1
2
4
9
12
6
-252
-181
Net Income, GAAP
- -
29.73
25.23
22.22
17.04
19.33
1.89
- -
- -
Effective Tax Rate (%)
-3.08
0.59
1.28
3.24
6.28
7.14
2.66
-93.95
-66.89
Profit Margin (%)
-22
-8
17
9
14
11
-162
-277
28
Working Capital
- -
8
32
30
34
37
77
24
313
LT Debt
51
114
116
139
147
158
555
300
280
Total Equity
- -
0.76
2.4
2.26
6.43
6.99
1.3
- -
- -
Return on Invested Capital (%)
- -
3.78
5.02
8.41
15.37
16.24
9.14
- -
- -
Return on Capital (%)
- -
5.22
11.4
22.11
35.66
34.24
14.05
-596.34
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
28
359
43
LT Borrowings
297
290
292
LT Finance Leases
14
24
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
374
363
84

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
274
187
179
Cash, Cash Equivalents & STI
12
14
- -
Accounts Receivable, Net
37
39
31
Inventories
160
90
93
Total Current Liabilities
140
464
151
Payables & Accruals
- -
- -
- -
ST Debt
28
359
43
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.55%
-46.02%
Free Cash Flow
- -
-2,736.67%
144.47%
Net Income, GAAP
- -
-776.25%
-4,114.78%
Sales/Revenue/Turnover
- -
14.42%
13.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
46
65
87
236
2025
81
52
71
78
268
2026
69
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.01
0.89
-0.04
0.31
2025
-0.06
-1.35
0.15
-6.49
-12.23
2026
-1.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Fermentalg S.A. (FALG.PA)
InnoCare Pharma Limited (INCPF)
Allogene Therapeutics, Inc. (ALLO)
Suzhou Ribo Life Science Co (6938.HK)
Level Biotechnology Inc. (3118.TWO)
Chemomab Therapeutics Ltd. (CMMB)
Business
Magle Chemoswed Holding AB (publ) (MAGLE.ST) is a Sweden-based holding company that operates as a contract development and manufacturing organization (CDMO) serving the pharmaceutical and medical device industries; it conducts research, development, and manufacturing in pharmaceutical chemistry and technology through subsidiaries including Magle Chemoswed AB, Adroit Science AB, Magle PharmaCept, and Magle Biopolymers A/S. The company provides comprehensive services from analytical development, including methods for product release and characterization; process development; solid-state expertise in crystallization, polymorph screening, salt formation, and particle engineering; cGMP and ISO 13485-compliant manufacturing in five dedicated suites; fill-and-finish operations for small-scale vial filling; and inhalation drug administration support; it specializes in active pharmaceutical ingredients (APIs) such as warfarin sodium (anticoagulant), melperone hydrochloride (antipsychotic), isradipine (calcium channel blocker for hypertension), amantadine sulfate (for central nervous system disorders), and benserazide hydrochloride (for Parkinson's disease treatment); it also offers custom synthesis and modification of dextran derivatives for drug delivery, medical devices, and diagnostics, alongside consultancy in material characterization and solid-phase analysis. Founded in 1944 and headquartered in Malmö, Sweden, Magle Chemoswed Holding employs approximately 158 people and targets pharmaceutical companies globally with GMP-compliant, regulatory-ready solutions meeting EMA and FDA standards. Recent developments include the 2024 merger with Amniotics and pK Chemicals to expand contract development and manufacturing capabilities; the April 2025 completion of the acquisition of all shares in Saving Chlora AB; and a December 2025 strategic distribution agreement with Rifa Pharma for SmartPAN and SmartGEL products in India, enhancing market presence in embolization and wound care technologies.